Clinical Trial Update: Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating anti-CD20 therapy (rituximab) for metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Medical University of Vienna | Conditions: Stage III Melanoma, Stage IV Melanoma | Phase 2 | Status: COMPLETED